R. Mohan

Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide α', β'-epoxyketones

C. Crews, U. Splittgerber, M. Elofsson, 1999 .

The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest.

C. Crews, J. Yeh, R. Mohan, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3, 5-difluoro-6-[3-(4, 5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylgl y cine (ZK-807834): a potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa.

M. Whitlow, D. Davey, K. Eagen, 1998, Journal of medicinal chemistry.

Crystallographic analysis of potent and selective factor Xa inhibitors complexed to bovine trypsin.

M. Whitlow, D. Davey, M. Morrissey, 1999, Acta crystallographica. Section D, Biological crystallography.

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity.

C. Crews, B. Kwok, M. Elofsson, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Small-molecule inhibitors of the cell cycle.

C. Crews, R. Mohan, Craig M. Crews, 2000, Current opinion in chemical biology.

18F-labelling of a potent nonpeptide CCR1 antagonist: synthesis of 1-(5-chloro-2-{2-[(2R)-4-(4-[18F]fluorobenzyl)-2-methylpiperazin-1-yl]-2-oxoethoxy}phenyl)urea in an automated module

J. Steinbach, M. Halks-Miller, M. Friebe, 2006 .

Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones.

C. Crews, U. Splittgerber, M. Elofsson, 1999, Chemistry & biology.